메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Berlin Heals Holding AG Successfully Raises Over 5Million USD Round for Advancing New Less Invasive Approaches

ZUG, Switzerland, Sept. 1, 2025 -- Berlin Heals Holding AG, a MedTech company, is developing a novel treatment to reverse remodel and recover from Heart Failure. After a successful First-In-Human study in 2019 followed by sustaining long-term results and a successful Randomized Controlled Trial completed in 2024, the company has been developing a new approach to implant the device less invasively in an outpatient cardiac cath lab procedure. The implant consists of two electrodes connected to an implantable generator that provides constant direct microcurrent across the
- 김갑성 기자
- 2025-09-01 15:00
Rosti to Showcase Next-Generation Medical Manufacturing Solutions at MedTec China 2025

SHANGHAI, Sept. 1, 2025 -- Shanghai, September 24–26, 2025 – Stand 1D402 Rosti Integrated Manufacturing Solutions (Suzhou) Co., Ltd., part of the Rosti Group, will highlight its expanding medical device capabilities at MedTec China 2025, showcasing advanced medical injection moulding, turnkey assembly, and innovative prototyping solutions that meet the most stringent international medical standards. Pioneering Medical Device Manufacturing As a trusted CDMO partner, Rosti delivers end-to-end solutions—from concept to commercialization. Leveraging deep industry expe
- 김갑성 기자
- 2025-09-01 14:53
CMEF 2025: Promoting Holistic and High-Quality Development of Medical and Health Industry

GUANGZHOU, China, Sept. 1, 2025 -- The 92nd China International Medical Equipment Fair (CMEF 2025) Autumn Exhibition is set to take place from September 26 to 29 at the China Import and Export Fair Complex (Canton Fair Complex) in Guangzhou. Themed "Health, Innovation, Collaboration," the tradeshow will bring together the global healthcare industry to explore new opportunities for high-quality development. As an international top-tier exhibition covering the entire industry chain, CMEF unites global stakeholders to drive high‑quality healthcare growth through innovati
- 김갑성 기자
- 2025-09-01 13:06
Jenscare, releases 2025H1 interim results

BEIJING, Sept. 1, 2025 -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with TTVR breakthroughs, achieved milestones in its product portfolio globally, and just released its interim results for 2025H1 ended June 30, 2025. Business Overviews: In 2025H1, significant progress was achieved across its product pipeline in the interventional treatment for tricuspid, aortic and mitral valve diseases, establishing a diversified and high-potential product portfolio. More importantly, the Company continue
- 황정호 기자
- 2025-09-01 13:00
Jenscare Announces 2025H1 Interim Results

BEIJING, Sept. 1, 2025 -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases, achieved key milestones in its product portfolio and just announced its interim results for 2025H1. Business Highlights: Big Movement in Commercialization, Registration and Clinical LuX-Valve Series, TTVR system In China, the multicenter clinical trial for NMPA approval has entered long-term follow-up phase, demonstrating excellent results. The r
- 김갑성 기자
- 2025-09-01 09:00
The Veteran Suite partners with QENDO to advocate for female veteran care

SYDNEY, Sept. 1, 2025 -- The Veteran Suite, a medical centre exclusively for Australian veterans and their families, has launched a new partnership with QENDO, an Australian organisation providing support and education for those affected by endometriosis, adenomyosis, PCOS, infertility or pelvic pain. Partnering with QENDO, The Veteran Suite aims to deliver targeted support for female veterans and their families, and raise awareness as to the support that both QENDO and The Veteran Suite can provide. The Veteran Suite was founded as a telehealth-first clinic with a mission to reduce ba
- 김갑성 기자
- 2025-09-01 08:00
성장의 관문: 제8회 CIIE의 혁신과 기회

[ 메디채널 황정호 기자 ] 상하이, 2025년 8월 30일 -- 변화하는 글로벌 경제 속에서 중국국제수입박람회(China International Import Expo, CIIE)가 여전히 세계 기업들에 중요한 관문 역할을 하고 있다. 제8회 CIIE 준비가 순조롭게 진행 중인 가운데, 이번 박람회는 다시 한번 혁신을 선보이고 협력을 촉진하며 역동적인 중국 시장으로의 접근성을 확대할 예정이다. 글로벌 기업들은 CIIE라는 핵심 플랫폼을 활용해 중국의 거대한 시장으로 진입해 왔다. 다수의 참가 기업이 단순한 전시업체에서 투자자로 성장했고, 수많은 전시품은 시장성 있는 상품으로 전환됐다. 예를 들어, 노바티스(Novartis)는 제4회 CIIE에서 방사성 리간드 치료제(Radioligand Therapy, RLT)를 처음 선보였다. CIIE의 파급 효과 덕분에 노바티스는 제7회 박람회에서 GE 헬스케어 차이나(GE Healthcare China), 상하이 제약 지주(Shanghai Pharmaceutical Holding), 충칭 제약 지주(Chongqing Pharmaceutical Holding)와 전략적 협약을 체결해 중국
- 황정호 기자
- 2025-08-30 20:44
제이씨바이오•MGI 테크, 한국 내 멀티오믹스 혁신 촉진 위한 DCS 연구소 프로젝트 협력 발표

창춘, 중국 2025년 8월 30일 -- 생명과학 분야 혁신을 주도하는 핵심 도구와 기술 개발을 전문으로 하는 MGI 테크(MGI Tech Co., Ltd., 이하 'MGI')와 한국의 대표적인 바이오테크 기업 제이씨바이오가 획기적인 협업인 DCS 랩 프로젝트(DCS Lab Project)에 착수하기 위한 양해각서(MoU)를 체결했다. 본 프로젝트의 목표는 한국에서 ▲멀티오믹스 연구(multi-omics research) ▲혁신적 시퀀싱 응용 ▲정밀의학 ▲임상 전환 ▲인공지능(AI) 기반 데이터 분석을 가속하는 것이다. MGI의 첨단 오믹스 기술과 제이씨바이오의 현지 전문성을 결합하는 이번 파트너십은 연구자와 임상의에게 도움을 주면서 유전체학 및 생명공학 분야 지역 리더로서 한국의 역할을 강화할 것으로 기대된다. 한국의 유전체학 생태계 강화 멀티오믹스 연구가 의료계를 재편하고 있는 시대에 MGI 테크와 제이씨바이오의 협력은 한국의 유전체학 생태계 강화에 중요한 이정표가 되고 있다. 본 프로젝트는 MGI의 독자적인 숏리드(short-read) 및 롱리드(long-read) 시퀀싱 기술을 결합함으로써 제이씨
- 김갑성 기자
- 2025-08-30 15:37
LifeTech Scientific Corporation Announces 2025 Interim Results: Core Business Demonstrated Resilience, Domestic and Overseas Sales Both Increased

HONG KONG, Aug. 30, 2025 -- LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group", stock code: 1302.HK), a medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and peripheral vascular diseases, today announced its unaudited consolidated results for the six months ended 30 June 2025 (the "Reporting Period"). Revenue Growth: The Group achieved revenue of approximately RMB676.7 million during the Reporting Period, repres
- 김갑성 기자
- 2025-08-30 01:07
Jacobio Pharma Announces 2025 Interim Results

BEIJING and SHANGHAI and BOSTON, Aug. 30, 2025 -- Jacobio Pharma (1167.HK) today announced its interim results for the six months ended June 30, 2025. During the reporting period, the Company achieved revenue of RMB45.7 million, representing a 100% increase compared with the same period in 2024. Research and development (R&D) expenses amounted to RMB93.2 million. The net loss for the first half of 2025 was RMB59.0 million, narrowing by 65.1% compared with the same period in 2024. As of June 30, 2025, Jacobio maintained cash and bank balances, and investments in capital protected
- 김갑성 기자
- 2025-08-30 00:25

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-09-04_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 04일 12시 20분